ArticleEmerging microbes & infections2021
EasyNAT MTC assay: A simple, rapid, and low-cost cross-priming amplification method for the detection of mycobacterium tuberculosis suitable for point-of-care testing.
Article in Emerging microbes & infections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Molecular Detection of Balantioides coli in Pigs Employing the Traditional PCR and a Novel Cross-Priming Amplification-Based Lateral Flow Assay.Transboundary and emerging diseases · 2026Article
- Hierarchical integration of mNGS, PCR, and other conventional methods for precision TB diagnostics.Microbiology spectrum · 2025Article
- Rapid and simple detection of Chlamydia trachomatis and Neisseria gonorrhoeae using the EasyNAT CT/NG assay based on cross-priming amplification.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Article
- [Clinical value of automated EasyNAT system for the diagnosis of tuberculosis in paraffin-embedded tissues].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Article
- Accurate detection of influenza A virus by use of a novel cross-priming isothermal amplification-based point-of-care assay.Microbiology spectrum · 2024Article
- Rapid detection ofJournal of clinical microbiology · 2024Article
- Article
- ddPCR provides a sensitive test compared with GeneXpert MTB/RIF and mNGS for suspectedFrontiers in cellular and infection microbiology · 2023Article
- Time-trend analysis of tuberculosis diagnosis in Shenzhen, China between 2011 and 2020.Frontiers in public health · 2023Article
- EasyNAT MP Assay: A Simple, Rapid, and Low-Cost Method to Detect Mycoplasma pneumoniae Using Cross-Priming Amplification Technology.Molecular diagnosis & therapy · 2022Article
- GeneXpert MTB/RIF combined with conventional methods for tuberculosis in Shanghai Regional Medical Center: a retrospective diagnostic study.Annals of translational medicine · 2022Article
- Research of childhood tuberculosis in suspected populations by molecular methods: A multicenter study in China.Frontiers in cellular and infection microbiology · 2022Article
- A Novel Cross-Priming Amplification-Based Assay for Tuberculosis Diagnosis in Children Using Gastric Aspirate.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More sensitive, rapid, and affordable diagnostic tools for pulmonary tuberculosis (PTB) are urgently needed. This study aimed to assess the performance of EasyNAT MTC (abbreviation: EasyNAT) (Ustar Biotechnologies, China), a novel isothermal amplification method with a turnaround time of less than two hours that requires a few manual steps to process the sputum. Sputum samples from 249 patients with suspected PTB were subjected to smear, culture, Xpert MTB/RIF (Cepheid, USA) and EasyNAT assay testing. Of the 169 PTB patients, EasyNAT detected more PTB patients than Xpert (72.19% vs. 61.54%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.